Unicycive Therapeutics (UNCY) Competitors $4.20 -0.14 (-3.23%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.32 +0.12 (+2.74%) As of 08/1/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock UNCY vs. ELDN, MDWD, BTMD, CRGX, NLTX, VTYX, ACIU, LRMR, CGC, and YMABShould you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include Eledon Pharmaceuticals (ELDN), MediWound (MDWD), biote (BTMD), CARGO Therapeutics (CRGX), Neoleukin Therapeutics (NLTX), Ventyx Biosciences (VTYX), AC Immune (ACIU), Larimar Therapeutics (LRMR), Canopy Growth (CGC), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical products" industry. Unicycive Therapeutics vs. Its Competitors Eledon Pharmaceuticals MediWound biote CARGO Therapeutics Neoleukin Therapeutics Ventyx Biosciences AC Immune Larimar Therapeutics Canopy Growth Y-mAbs Therapeutics Unicycive Therapeutics (NASDAQ:UNCY) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk. Which has better earnings & valuation, UNCY or ELDN? Eledon Pharmaceuticals has lower revenue, but higher earnings than Unicycive Therapeutics. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUnicycive Therapeutics$680K78.07-$36.73M-$5.10-0.82Eledon PharmaceuticalsN/AN/A-$36.18M-$2.10-1.61 Is UNCY or ELDN more profitable? Eledon Pharmaceuticals' return on equity of -79.54% beat Unicycive Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Unicycive TherapeuticsN/A -277.30% -61.53% Eledon Pharmaceuticals N/A -79.54%-41.62% Which has more volatility & risk, UNCY or ELDN? Unicycive Therapeutics has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of -0.15, suggesting that its stock price is 115% less volatile than the S&P 500. Does the media favor UNCY or ELDN? In the previous week, Unicycive Therapeutics had 3 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 6 mentions for Unicycive Therapeutics and 3 mentions for Eledon Pharmaceuticals. Unicycive Therapeutics' average media sentiment score of 0.31 beat Eledon Pharmaceuticals' score of 0.12 indicating that Unicycive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eledon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders have more ownership in UNCY or ELDN? 40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 10.7% of Unicycive Therapeutics shares are held by insiders. Comparatively, 12.3% of Eledon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate UNCY or ELDN? Unicycive Therapeutics currently has a consensus price target of $60.00, indicating a potential upside of 1,328.57%. Eledon Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 195.86%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Unicycive Therapeutics is more favorable than Eledon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Unicycive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Eledon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryUnicycive Therapeutics beats Eledon Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UNCY vs. The Competition Export to ExcelMetricUnicycive TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.09M$2.50B$5.53B$9.37BDividend YieldN/A1.80%4.74%4.12%P/E Ratio-0.828.9728.8823.79Price / Sales78.07687.56440.8796.30Price / CashN/A155.1435.0757.18Price / Book5.834.838.255.54Net Income-$36.73M$31.62M$3.25B$259.88M7 Day Performance-13.76%-5.28%-3.75%-4.67%1 Month Performance-9.48%4.38%4.27%4.40%1 Year Performance-3.14%-2.49%25.83%17.91% Unicycive Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UNCYUnicycive Therapeutics2.3688 of 5 stars$4.20-3.2%$60.00+1,328.6%-1.6%$53.09M$680K-0.829Short Interest ↑ELDNEledon Pharmaceuticals2.1538 of 5 stars$3.69-0.3%$9.00+143.9%+17.0%$221.56MN/A0.0010MDWDMediWound1.924 of 5 stars$20.07-1.9%$32.25+60.7%+6.1%$221.13M$20.22M0.0080BTMDbiote2.9696 of 5 stars$4.01-0.2%$8.00+99.5%-48.0%$219.93M$197.19M6.18194News CoverageUpcoming EarningsCRGXCARGO Therapeutics2.2954 of 5 stars$4.52-1.1%$15.40+240.7%-73.1%$210.72MN/A0.00116High Trading VolumeNLTXNeoleukin TherapeuticsN/A$22.34-1.2%N/A-46.3%$209.95MN/A-7.1890Gap DownHigh Trading VolumeVTYXVentyx Biosciences2.7648 of 5 stars$2.95-6.6%$10.00+239.0%+17.4%$209.92MN/A-1.6930News CoverageShort Interest ↑ACIUAC Immune2.0985 of 5 stars$2.08+0.5%$12.00+476.9%-44.5%$207.85M$31.02M0.00140Positive NewsUpcoming EarningsLRMRLarimar Therapeutics2.2556 of 5 stars$3.26+1.6%$18.50+467.5%-58.7%$205.53MN/A0.0030Positive NewsUpcoming EarningsCGCCanopy Growth0.4542 of 5 stars$1.12+2.8%N/A-84.5%$200.41M$225.65M0.003,150News CoverageUpcoming EarningsYMABY-mAbs Therapeutics2.2113 of 5 stars$4.33+0.5%$15.60+260.3%-61.1%$196.06M$87.68M-6.77150News CoverageShort Interest ↑ Related Companies and Tools Related Companies Eledon Pharmaceuticals Alternatives MediWound Alternatives biote Alternatives CARGO Therapeutics Alternatives Neoleukin Therapeutics Alternatives Ventyx Biosciences Alternatives AC Immune Alternatives Larimar Therapeutics Alternatives Canopy Growth Alternatives Y-mAbs Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UNCY) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
